Read our latest updates & insights

On 12 January 2026, an appellate Division of the High Court of Delhi issued its judgment overturning the grant of a preliminary injunction awarded to Bristol Myers Squibb (BMS) in July 2025, restraining Zydus’ Indian launch of nivolumab ZRC-3276, biosimilar to BMS’ Opdivo®....

On 12 January 2026, Ono Pharmaceutical announced that the Taiwan Food and Drug Administration has approved a new indication for Opdivo® (nivolumab) intravenous infusion in combination with Yervoy® (ipilimumab), for the treatment of adult patients with unresectable or metast...

On 9 January 2026, Aurobindo Pharma announced in a regulatory filing that its subsidiary, CuraTeQ Biologics, has received approval from Health Canada for Dyrupeg®, biosimilar to Amgen’s Neulasta® (pegfilgrastim).  In the same regulatory filing, CuraTeq also disclosed that i...

On 9 January 2026, Boan Biotech announced that it has received regulatory approval from Bolivia’s National Agency of Medicines and Health Technologies (AGEMED) for BA6101, its 60 mg denosumab injection, biosimilar to Amgen’s Prolia®.  BA6101 is approved for the same i...

On 8 January 2026, Takeda announced that it has entered a global collaboration and licence agreement with Halozyme Therapeutics, Inc, which grants Takeda exclusive rights to Halozyme’s Enhanze® drug delivery technology for use with Takeda’s Entyvio® (vedolizumab).

Un...

On 8 January 2026, the Munich Regional Court granted Regeneron and Bayer preliminary injunctions (PIs) preventing STADA, Hexal, Celltrion and Advanz Pharma from marketing their aflibercept biosimilars in Germany and requiring them to recall any products already on the marke...

GSK’s Nucala® (mepolizumab) has received approval in China and the UK as an add-on maintenance treatment for adult patients with inadequately controlled COPD characterised by raised blood eosinophils.

The approval by China’s National Medical Products Administration (...